AU2017248807A1 - Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis - Google Patents
Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis Download PDFInfo
- Publication number
- AU2017248807A1 AU2017248807A1 AU2017248807A AU2017248807A AU2017248807A1 AU 2017248807 A1 AU2017248807 A1 AU 2017248807A1 AU 2017248807 A AU2017248807 A AU 2017248807A AU 2017248807 A AU2017248807 A AU 2017248807A AU 2017248807 A1 AU2017248807 A1 AU 2017248807A1
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- inhibitor
- pct
- mitosis
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- QSGBYBVSTCPRGT-UHFFFAOYSA-N CC(Nc(cc1)cc(Nc2c(c3c(cc4)nc(C(OC)=N)[s]3)c4ncn2)c1Cl)=O Chemical compound CC(Nc(cc1)cc(Nc2c(c3c(cc4)nc(C(OC)=N)[s]3)c4ncn2)c1Cl)=O QSGBYBVSTCPRGT-UHFFFAOYSA-N 0.000 description 1
- BGDLTPQNXVMIQO-UHFFFAOYSA-N COC(c([s]c1c23)nc1ccc2ncnc3Nc(ccc(Br)c1)c1Cl)=N Chemical compound COC(c([s]c1c23)nc1ccc2ncnc3Nc(ccc(Br)c1)c1Cl)=N BGDLTPQNXVMIQO-UHFFFAOYSA-N 0.000 description 1
- ADEKVGOKZALRKK-SGAVDWSDSA-N COC(c1nc(ccc(/N=C\N=C)c2CNc(ccc(F)c3)c3Cl)c2[s]1)=N Chemical compound COC(c1nc(ccc(/N=C\N=C)c2CNc(ccc(F)c3)c3Cl)c2[s]1)=N ADEKVGOKZALRKK-SGAVDWSDSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2023214240A AU2023214240A1 (en) | 2016-04-15 | 2023-08-08 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323583P | 2016-04-15 | 2016-04-15 | |
| US62/323,583 | 2016-04-15 | ||
| PCT/US2017/027734 WO2017181087A1 (en) | 2016-04-15 | 2017-04-14 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023214240A Division AU2023214240A1 (en) | 2016-04-15 | 2023-08-08 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2017248807A1 true AU2017248807A1 (en) | 2018-10-25 |
Family
ID=60039311
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017248807A Abandoned AU2017248807A1 (en) | 2016-04-15 | 2017-04-14 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
| AU2023214240A Abandoned AU2023214240A1 (en) | 2016-04-15 | 2023-08-08 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023214240A Abandoned AU2023214240A1 (en) | 2016-04-15 | 2023-08-08 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10314843B2 (OSRAM) |
| EP (1) | EP3443351A4 (OSRAM) |
| JP (1) | JP7278776B2 (OSRAM) |
| KR (2) | KR20230020560A (OSRAM) |
| CN (1) | CN109313197A (OSRAM) |
| AU (2) | AU2017248807A1 (OSRAM) |
| BR (1) | BR112018071023A2 (OSRAM) |
| CA (1) | CA3020978A1 (OSRAM) |
| IL (2) | IL292475A (OSRAM) |
| MX (2) | MX2018012508A (OSRAM) |
| WO (1) | WO2017181087A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109562176A (zh) | 2016-04-15 | 2019-04-02 | 费利克斯疗法公司 | 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合 |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20150104T1 (xx) * | 2009-09-11 | 2015-03-13 | Amgen, Inc. | N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(4-metil-2-thienil)-1-ftalazinamin za primjenu u tretmanu kancera rezistentnog na antimitotiäśke agense |
| US20120184562A1 (en) | 2011-01-19 | 2012-07-19 | Kin-Chun Luk | 1,6- and 1,8-naphthyridines |
| PL2744797T3 (pl) * | 2011-08-19 | 2016-01-29 | Diaxonhit | Inhibitory dyrk1 i ich zastosowanie |
| FR2993317B1 (fr) | 2012-07-16 | 2014-08-15 | Snecma | Carter de turbomachine dans un materiau composite et procede de fabrication associe |
| US20150292032A1 (en) * | 2012-10-10 | 2015-10-15 | Felicitex Therapeutics, Inc. | Treatment of cancer by targeting quiescent cancer cells |
| EP3007692A1 (en) * | 2013-06-11 | 2016-04-20 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor |
| CA2854542A1 (en) * | 2013-06-18 | 2014-12-18 | 4Sc Discovery Gmbh | Method of inhibiting dyrk1b |
| US9566280B2 (en) * | 2014-01-28 | 2017-02-14 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| PE20170127A1 (es) * | 2014-03-20 | 2017-03-30 | Samumed Llc | Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas |
| US20170304313A1 (en) | 2014-10-06 | 2017-10-26 | Novartis Ag | Therapeutic Combination For The Treatment Of Cancer |
| CN108135871B (zh) * | 2015-07-23 | 2022-11-04 | 博蔚医药生物科技股份有限公司 | 阻断疾病的泛素化-蛋白酶体系统的胺萘醌化合物及医药组合物 |
| CN109562176A (zh) | 2016-04-15 | 2019-04-02 | 费利克斯疗法公司 | 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合 |
-
2017
- 2017-04-14 BR BR112018071023A patent/BR112018071023A2/pt not_active Application Discontinuation
- 2017-04-14 IL IL292475A patent/IL292475A/en unknown
- 2017-04-14 US US15/488,143 patent/US10314843B2/en active Active
- 2017-04-14 WO PCT/US2017/027734 patent/WO2017181087A1/en not_active Ceased
- 2017-04-14 CN CN201780037724.5A patent/CN109313197A/zh active Pending
- 2017-04-14 CA CA3020978A patent/CA3020978A1/en active Pending
- 2017-04-14 JP JP2018554360A patent/JP7278776B2/ja active Active
- 2017-04-14 EP EP17783296.1A patent/EP3443351A4/en not_active Withdrawn
- 2017-04-14 KR KR1020237002817A patent/KR20230020560A/ko not_active Ceased
- 2017-04-14 AU AU2017248807A patent/AU2017248807A1/en not_active Abandoned
- 2017-04-14 MX MX2018012508A patent/MX2018012508A/es unknown
- 2017-04-14 KR KR1020187033030A patent/KR102494172B1/ko active Active
-
2018
- 2018-10-11 IL IL262325A patent/IL262325B/en unknown
- 2018-10-12 MX MX2022012146A patent/MX2022012146A/es unknown
-
2019
- 2019-06-10 US US16/436,305 patent/US20190290651A1/en not_active Abandoned
-
2021
- 2021-12-21 US US17/558,204 patent/US20220110941A1/en not_active Abandoned
-
2023
- 2023-08-08 AU AU2023214240A patent/AU2023214240A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA3020978A1 (en) | 2017-10-19 |
| US20190290651A1 (en) | 2019-09-26 |
| KR102494172B1 (ko) | 2023-02-02 |
| IL292475A (en) | 2022-06-01 |
| AU2023214240A1 (en) | 2023-08-24 |
| MX2022012146A (es) | 2022-10-21 |
| US20220110941A1 (en) | 2022-04-14 |
| MX2018012508A (es) | 2019-07-08 |
| WO2017181087A1 (en) | 2017-10-19 |
| CN109313197A (zh) | 2019-02-05 |
| IL262325B (en) | 2022-06-01 |
| KR20230020560A (ko) | 2023-02-10 |
| US20170296542A1 (en) | 2017-10-19 |
| KR20180130575A (ko) | 2018-12-07 |
| JP7278776B2 (ja) | 2023-05-22 |
| US10314843B2 (en) | 2019-06-11 |
| EP3443351A1 (en) | 2019-02-20 |
| BR112018071023A2 (pt) | 2019-02-05 |
| EP3443351A4 (en) | 2019-12-18 |
| IL262325A (en) | 2018-11-29 |
| JP2019511553A (ja) | 2019-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220110941A1 (en) | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis | |
| US11202779B2 (en) | Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors | |
| WO2023140846A1 (en) | Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway | |
| US20220168333A1 (en) | Combination Treatment for Hematological Cancers | |
| JP2015506376A (ja) | Ｃｄｋ８／ｃｄｋ１９選択的阻害剤、ならびに癌のための抗転移および化学防御の方法におけるそれらの使用 | |
| EA201201161A1 (ru) | Пирролопиримидины в качестве ингибиторов cdk4/6 | |
| US9573899B2 (en) | USP7 inhibitor compounds and methods of use | |
| WO2020047487A1 (en) | Methods for treating cancer with rorgamma inhibitors and statins | |
| US20230226061A1 (en) | Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway | |
| MX2024013264A (es) | Compuestos de 7-(pirimidin-4-il)quinolin-4(1h)-ona sustituidos como inhibidores de cinasas dependientes de ciclina | |
| WO2020227202A1 (en) | Compositions and methods for treating cancer | |
| US9782387B2 (en) | Compositions and methods for treating hematological malignancies | |
| CA2986547C (en) | A compound for anti-cancer therapy that acts by targeting gof mutant p53 and stimulates p73 to restore the p53 pathway signaling | |
| WO2017069913A1 (en) | Chalcone compounds | |
| HK40097706A (en) | Combinations of imetelstat and venetoclax for use in the treatment of haematological cancer | |
| HK40002948B (en) | Combinations of imetelstat and venetoclax for the treatment of acute myeloid leukaemia | |
| HK40002948A (en) | Combinations of imetelstat and venetoclax for the treatment of acute myeloid leukaemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |